Cargando…

An engineered recombinant protein containing three structural domains in SARS-CoV-2 S2 protein has potential to act as a pan-human coronavirus entry inhibitor or vaccine antigen

The threat to global health caused by three highly pathogenic human coronaviruses (HCoV), SARS-CoV-2, MERS-CoV and SARS-CoV, calls for the development of pan-HCoV therapeutics and vaccines. This study reports the design and engineering of a recombinant protein designated HR1LS. It contains three lin...

Descripción completa

Detalles Bibliográficos
Autores principales:	Wang, Xinling, Sun, Lujia, Liu, Zezhong, Xing, Lixiao, Zhu, Yun, Xu, Wei, Xia, Shuai, Lu, Lu, Jiang, Shibo
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Taylor & Francis 2023
Materias:	Coronaviruses
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10424610/ https://www.ncbi.nlm.nih.gov/pubmed/37534910 http://dx.doi.org/10.1080/22221751.2023.2244084

Ejemplares similares

Application of “B+1” heterologous boosting strategy for preventing infection of SARS-CoV-2 variants with resistance to broad-spectrum coronavirus vaccines
por: Liu, Zezhong, et al.
Publicado: (2023)

SARS-CoV-2 Omicron subvariants exhibit distinct fusogenicity, but similar sensitivity, to pan-CoV fusion inhibitors
por: Xia, Shuai, et al.
Publicado: (2023)

Spike mutations contributing to the altered entry preference of SARS-CoV-2 omicron BA.1 and BA.2
por: Hu, Bingjie, et al.
Publicado: (2022)

Obatoclax inhibits SARS-CoV-2 entry by altered endosomal acidification and impaired cathepsin and furin activity in vitro
por: Mao, Binli, et al.
Publicado: (2022)

Structure-based design of oligomeric receptor-binding domain (RBD) recombinant proteins as potent vaccine candidates against SARS-CoV-2
por: Zhang, Ting, et al.
Publicado: (2023)

An engineered 5-helix bundle derived from SARS-CoV-2 S2 pre-binds sarbecoviral spike at both serological- and endosomal-pH to inhibit virus entry
por: Lin, Xi, et al.
Publicado: (2022)

Safety and immunogenicity of SCB-2019, an adjuvanted, recombinant SARS-CoV-2 trimeric S-protein subunit COVID-19 vaccine in healthy 12–17 year-old adolescents
por: Lopez, Pio, et al.
Publicado: (2023)

Efficacy of heterologous boosting against SARS-CoV-2 using a recombinant interferon-armed fusion protein vaccine (V-01): a randomized, double-blind and placebo-controlled phase III trial
por: Wang, Xuan-Yi, et al.
Publicado: (2022)

Mapping cross-variant neutralizing sites on the SARS-CoV-2 spike protein
por: Xu, Shiqi, et al.
Publicado: (2022)

A second functional furin site in the SARS-CoV-2 spike protein
por: Zhang, Yue, et al.
Publicado: (2022)

The role of SARS-CoV-2 nucleocapsid protein in antiviral immunity and vaccine development
por: Yu, Haiyun, et al.
Publicado: (2023)

A new screening system for entry inhibitors based on cell-to-cell transmitted syncytia formation mediated by self-propagating hybrid VEEV-SARS-CoV-2 replicon
por: Li, Na, et al.
Publicado: (2022)

A novel DNA and protein combination COVID-19 vaccine formulation provides full protection against SARS-CoV-2 in rhesus macaques
por: Li, Yuzhong, et al.
Publicado: (2021)

Identification of a promiscuous conserved CTL epitope within the SARS-CoV-2 spike protein
por: Jiang, Sheng, et al.
Publicado: (2022)

Identification of three conserved linear B cell epitopes on the SARS-CoV-2 spike protein
por: Wang, Aiping, et al.
Publicado: (2022)

Age-associated SARS-CoV-2 breakthrough infection and changes in immune response in a mouse model
por: Chen, Yanxia, et al.
Publicado: (2022)

Mouse study of combined DNA/protein COVID-19 vaccine to boost high levels of antibody and cell mediated immune responses
por: He, Qian, et al.
Publicado: (2022)

Identification of a recombinant equine coronavirus in donkey, China
por: Qi, Peng-Fei, et al.
Publicado: (2022)

Pathogen-host adhesion between SARS-CoV-2 spike proteins from different variants and human ACE2 studied at single-molecule and single-cell levels
por: Zhang, Xiaoxu, et al.
Publicado: (2022)

Homologous or heterologous booster of inactivated vaccine reduces SARS-CoV-2 Omicron variant escape from neutralizing antibodies
por: Wang, Xun, et al.
Publicado: (2022)

Isolation of SARS-CoV-2 strains carrying a nucleotide mutation, leading to a stop codon in the ORF 6 protein
por: Delbue, Serena, et al.
Publicado: (2021)

A novel cyclic γ-AApeptide-based long-acting pan-coronavirus fusion inhibitor with potential oral bioavailability by targeting two sites in spike protein
por: Xue, Songyi, et al.
Publicado: (2022)

A novel RBD-protein/peptide vaccine elicits broadly neutralizing antibodies and protects mice and macaques against SARS-CoV-2
por: Wang, Shixia, et al.
Publicado: (2022)

Transcriptomic analysis of the innate immune signatures of a SARS-CoV-2 protein subunit vaccine ZF2001 and an mRNA vaccine RRV
por: Wang, Qian, et al.
Publicado: (2022)

Heterologous boosting with third dose of coronavirus disease recombinant subunit vaccine increases neutralizing antibodies and T cell immunity against different severe acute respiratory syndrome coronavirus 2 variants
por: Zhao, Zhuxiang, et al.
Publicado: (2022)

A booster of Delta-Omicron RBD-dimer protein subunit vaccine augments sera neutralization of Omicron sub-variants BA.1/BA.2/BA.2.12.1/BA.4/BA.5
por: Duan, Minrun, et al.
Publicado: (2023)

Possible recombination between two variants of concern in a COVID-19 patient
por: He, Yaqing, et al.
Publicado: (2022)

SARS-CoV-2 Omicron variant shows less efficient replication and fusion activity when compared with Delta variant in TMPRSS2-expressed cells
por: Zhao, Hanjun, et al.
Publicado: (2022)

Structure of the multiple functional domains from coronavirus nonstructural protein 3
por: Li, Mengxia, et al.
Publicado: (2021)

Impaired antibody response to inactivated COVID-19 vaccines in hospitalized patients with type 2 diabetes
por: Zhou, Xiaoying, et al.
Publicado: (2023)

A recombinant Mycobacterium smegmatis-based surface display system for developing the T cell-based COVID-19 vaccine
por: Wen, Ziyu, et al.
Publicado: (2023)

Potential recombination between SARS-CoV-2 and MERS-CoV: calls for the development of Pan-CoV vaccines
por: Wang, Qiao, et al.
Publicado: (2023)

Aggravated pneumonia and diabetes in SARS-CoV-2 infected diabetic mice
por: Huang, Qing, et al.
Publicado: (2023)

SARS-CoV-2 IgG seropositivity after the severe Omicron wave of COVID-19 in Hong Kong
por: Poon, Rosana Wing-Shan, et al.
Publicado: (2022)

Etesevimab in combination with JS026 neutralizing SARS-CoV-2 and its variants
por: Wang, Fengze, et al.
Publicado: (2022)

Safety and immunogenicity of inactivated SARS-CoV-2 vaccines in people living with HIV
por: Ao, Ling, et al.
Publicado: (2022)

Assessing SARS-CoV-2 vaccine hesitancy among the people living with and without HIV from May to September 2022 in Blantyre, Malawi
por: Mchawa, Chifundo, et al.
Publicado: (2023)

Omicron variant susceptibility to neutralizing antibodies induced in children by natural SARS-CoV-2 infection or COVID-19 vaccine
por: Chen, Lin-Lei, et al.
Publicado: (2022)

Furin cleavage is required for swine acute diarrhea syndrome coronavirus spike protein-mediated cell – cell fusion
por: Kim, Jinman, et al.
Publicado: (2022)

Induction of significant neutralizing antibodies against SARS-CoV-2 by a highly attenuated pangolin coronavirus variant with a 104nt deletion at the 3'-UTR
por: Lu, Shanshan, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_glkjjbl8cbm7abjmg2q2sqg4h1